BLINCYTO
35mcgBLINCYTO35mcg
BLINCYTO (Blinatumomab) 35mcg is a first-in-class BiTE® antibody by Amgen for B-cell precursor acute lymphoblastic leukemia (ALL).
Key Benefits
- First-in-class BiTE® antibody — revolutionary mechanism of action
- Significantly improved OS vs chemotherapy (TOWER trial: 7.7 vs 4.0 months)
- High MRD response rate (78% in BLAST trial)
- Practice-changing E1910 results in frontline ALL
- Off-the-shelf availability (no manufacturing delay like CAR-T)
- Active at picomolar concentrations
Contact Us for Pricing
Get competitive wholesale pricing for BLINCYTO 35mcg. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How BLINCYTO Works
Blinatumomab is a BiTE® (bispecific T-cell engager) antibody construct consisting of two single-chain variable fragments (scFv) connected by a short linker peptide. One scFv binds to CD19 on B-cell leukemia cells, while the other binds to CD3 on T-cells.
By simultaneously binding both targets, blinatumomab creates a direct immunological synapse between the patient's T-cells and the cancer cells. This activates endogenous T-cell cytotoxicity, leading to lysis of CD19-positive leukemic blasts through perforin/granzyme-mediated killing.
This mechanism is unique because it bypasses MHC-restricted antigen presentation, enabling potent anti-leukemic activity at picomolar concentrations. The small size of the BiTE construct (~55 kDa) also allows it to bridge cells more efficiently than conventional antibodies.
About BLINCYTO 35mcg
BLINCYTO (blinatumomab) 35mcg powder for solution for infusion by Amgen is the world's first bispecific T-cell engager (BiTE®) antibody approved for clinical use. It represents a revolutionary approach to immunotherapy by redirecting the patient's own T-cells to recognize and destroy CD19-positive leukemic cells. Blincyto is approved for relapsed or refractory B-cell precursor ALL in adults and children, and for ALL in first or second complete remission with minimal residual disease (MRD) ≥0.1%. The landmark TOWER trial demonstrated significant overall survival benefit, and the E1910/ECOG trial established Blincyto as part of frontline ALL treatment. As a licensed pharmaceutical supplier based in Turkey, we provide authentic Amgen BLINCYTO with validated cold chain shipping (2-8°C), certificate of authenticity, and competitive wholesale pricing for hospitals and hematology centers worldwide.
Common Uses
- Relapsed or refractory Ph- B-cell precursor ALL (adults and children)
- Ph- B-cell precursor ALL in CR1/CR2 with MRD ≥0.1%
- Frontline ALL consolidation (per E1910 data)
Dosage Information
BLINCYTO dosing varies by indication:
Relapsed/Refractory ALL (Adults ≥45kg):
MRD-Positive ALL:
Administered as continuous intravenous infusion over 24 hours using an infusion pump. Each vial contains 35 mcg blinatumomab.
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store at 2-8°C (36-46°F). Do not freeze. Protect from light. Store in original packaging. After reconstitution: stable up to 96 hours at 2-8°C or 48 hours at room temperature (≤27°C). Validated cold chain required for shipping.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About BLINCYTO
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
